Cardiomyoplasty: Long-term results in ischemic cardiomyopathy
| Autor: | S Fuchs, R Driever, R Bugenhagen, C Minale, H. O. Vetter |
|---|---|
| Rok vydání: | 2001 |
| Předmět: |
Heart transplantation
medicine.medical_specialty Ischemic cardiomyopathy Ejection fraction business.industry medicine.medical_treatment Biomedical Engineering Medicine (miscellaneous) Hemodynamics Bioengineering General Medicine 030204 cardiovascular system & hematology medicine.disease Sudden death Biomaterials Transplantation 03 medical and health sciences 0302 clinical medicine 030228 respiratory system Internal medicine Heart failure medicine Cardiology business Cardiomyoplasty |
| Zdroj: | The International Journal of Artificial Organs. 24:152-156 |
| ISSN: | 1724-6040 0391-3988 |
| DOI: | 10.1177/039139880102400307 |
| Popis: | Introduction Cardiomyoplasty was introduced into clinical practice in 1985 by Alain Carpentier. Since then, the procedure has been performed on more than 400 patients worldwide. The latissimus dorsi muscle is prepared maintaining the vascular supply, then the muscle flap is wrapped around the heart and connected to a cardiomyostimulator. The muscle is later stimulated synchronously with ventricular systole to augment the cardiac contractility. Methods To evaluate the long-term outcome of cardiomyoplasty, we investigated 3 patients electively undergoing this procedure in our hospital. All of these patients (2 male, 1 female) had severe chronic heart failure which did not respond to optimal medical treatment. The mean follow-up time was 42 months (range 24 - 60). All patients showed symptoms corresponding to NYHA class III, and one patient intermittently showed class IV despite conventional medical therapy. Patients were evaluated at 6-month intervals for 2 years with right heart catheterization, radionuclide scans, echocardiography, as well as questionnaires for assessing quality of life. Results There was no operative mortality. One patient experienced sudden death 2 years after operation. There were no significant changes in hemodynamic variables at 6, 12 or 24 months after surgery, respectively. Left ventricular ejection fraction increased from 20.0 (9.2 to 40.0 ± 7.1 % (p = 0.05) 1 year after operation. Considerable improvement of symptoms was seen in all, and 1 patient returned to work. NYHA-class decreased from 3.1 to 2.0 (p = 0.02). Conclusions Following cardiomyoplasty, patients may exhibit impressive clinical improvement with less striking changes of objective hemodynamic parameters. Thus, in our patients, dynamic cardiomyoplasty improves quality of life. We do not consider this treatment to be an alternative to heart transplantation. It does, however, provide a therapeutic option for patients for whom transplantation is contraindicated. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|